4D Molecular Therapeutics, Inc. Annual Net Cash Provided by (Used in) Financing Activities in USD from 2019 to 2023

Taxonomy & unit
us-gaap: USD
Description
Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.
Summary
4D Molecular Therapeutics, Inc. quarterly/annual Net Cash Provided by (Used in) Financing Activities history and growth rate from 2019 to 2023.
  • 4D Molecular Therapeutics, Inc. Net Cash Provided by (Used in) Financing Activities for the quarter ending March 31, 2024 was $319M, a 2800% increase year-over-year.
  • 4D Molecular Therapeutics, Inc. annual Net Cash Provided by (Used in) Financing Activities for 2023 was $157M, a 4984% increase from 2022.
  • 4D Molecular Therapeutics, Inc. annual Net Cash Provided by (Used in) Financing Activities for 2022 was $3.09M, a 97.4% decline from 2021.
  • 4D Molecular Therapeutics, Inc. annual Net Cash Provided by (Used in) Financing Activities for 2021 was $118M, a 57.7% decline from 2020.
Net Cash Provided by (Used in) Financing Activities, Annual (USD)
Net Cash Provided by (Used in) Financing Activities, YoY Annual Growth (%)
Period Value YoY Chg Change % Start Date End Date Report Filed
2023 $157M +$154M +4984% Jan 1, 2023 Dec 31, 2023 10-K 2024-02-29
2022 $3.09M -$115M -97.4% Jan 1, 2022 Dec 31, 2022 10-K 2024-02-29
2021 $118M -$161M -57.7% Jan 1, 2021 Dec 31, 2021 10-K 2023-03-15
2020 $279M +$281M Jan 1, 2020 Dec 31, 2020 10-K 2022-03-28
2019 -$2.2M Jan 1, 2019 Dec 31, 2019 10-K 2021-03-25
* An asterisk sign (*) next to the value indicates that the value is likely invalid.